Oxford Immunotec Global (NASDAQ:OXFD) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a report issued on Friday.

A number of other analysts also recently issued reports on OXFD. Cowen dropped their target price on shares of Oxford Immunotec Global from $22.00 to $19.00 and set an “outperform” rating for the company in a research report on Thursday, August 17th. Zacks Investment Research downgraded shares of Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research report on Wednesday, August 30th. BTIG Research assumed coverage on shares of Oxford Immunotec Global in a research report on Thursday, September 28th. They set a “buy” rating and a $21.00 target price for the company. Piper Jaffray Companies lowered their price objective on shares of Oxford Immunotec Global from $26.00 to $19.00 and set an “overweight” rating for the company in a research report on Tuesday, October 31st. Finally, ValuEngine downgraded shares of Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research report on Tuesday, October 31st. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. Oxford Immunotec Global presently has a consensus rating of “Hold” and a consensus target price of $19.75.

Oxford Immunotec Global (NASDAQ OXFD) traded up $0.52 on Friday, reaching $14.27. 382,314 shares of the company were exchanged, compared to its average volume of 179,209. Oxford Immunotec Global has a 12-month low of $12.19 and a 12-month high of $19.51. The company has a debt-to-equity ratio of 0.38, a current ratio of 4.72 and a quick ratio of 4.30.

In related news, Director Richard A. Sandberg sold 3,000 shares of the firm’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $13.35, for a total transaction of $40,050.00. Following the transaction, the director now directly owns 17,778 shares in the company, valued at $237,336.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Peter Wrighton-Smith sold 55,000 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $16.78, for a total value of $922,900.00. The disclosure for this sale can be found here. Corporate insiders own 8.11% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in OXFD. Voya Investment Management LLC lifted its stake in Oxford Immunotec Global by 16.0% during the second quarter. Voya Investment Management LLC now owns 13,345 shares of the company’s stock worth $224,000 after purchasing an additional 1,845 shares during the last quarter. Alliancebernstein L.P. bought a new stake in Oxford Immunotec Global in the second quarter valued at $247,000. Asymmetry Capital Management L.P. bought a new stake in Oxford Immunotec Global in the second quarter valued at $273,000. The Manufacturers Life Insurance Company lifted its stake in Oxford Immunotec Global by 8.8% in the second quarter. The Manufacturers Life Insurance Company now owns 18,631 shares of the company’s stock valued at $313,000 after buying an additional 1,500 shares during the last quarter. Finally, Rhumbline Advisers lifted its stake in Oxford Immunotec Global by 9.1% in the second quarter. Rhumbline Advisers now owns 24,500 shares of the company’s stock valued at $412,000 after buying an additional 2,053 shares during the last quarter. Hedge funds and other institutional investors own 89.35% of the company’s stock.

WARNING: “Oxford Immunotec Global (OXFD) Rating Increased to Hold at BidaskClub” was published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.watchlistnews.com/oxford-immunotec-global-oxfd-rating-increased-to-hold-at-bidaskclub/1769933.html.

About Oxford Immunotec Global

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.